PMID- 19558241
OWN - NLM
STAT- MEDLINE
DCOM- 20100201
LR  - 20090629
IS  - 1091-7691 (Electronic)
IS  - 0895-8378 (Linking)
VI  - 21 Suppl 1
DP  - 2009 Jul
TI  - Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung 
      models.
PG  - 104-9
LID - 10.1080/08958370903005769 [doi]
AB  - The aim of this study was to investigate the potential cytotoxicity of solid 
      lipid nanoparticles (SLN) for human lung as a suitable drug delivery system 
      (DDS). Therefore we used a human alveolar epithelial cell line (A549) and murine 
      precision-cut lung slices (PCLS) to estimate the tolerable doses of these 
      particles for lung cells. A549 cells (in vitro) and precision-cut lung slices (ex 
      vivo) were incubated with SLN20 (20% phospholipids in the lipid matrix of the 
      particles) and SLN50 (50% phospholipids in the lipid matrix of the particles) in 
      increasing concentrations. The cytotoxic effects of SLN were evaluated in vitro 
      by lactate dehydrogenase (LDH) and 
      3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
      Vitality of lung slices was controlled by staining with calcein AM/ethidium 
      homodimer 1 using confocal laser scanning microscopy and followed by quantitative 
      image analysis with IMARIS software. A549 cell line revealed a middle effective 
      concentration (EC(50)) for MTT assay for SLN20 of 4080 microg/ml and for SLN50 of 
      1520 microg/ml. The cytotoxicity in terms of LDH release showed comparable EC(50) 
      values of 3431 microg/ml and 1253 microg/ml for SLN20 and SLN50, respectively. 
      However, in PCLS we determined only SLN50 cytotoxic values with a concentration 
      of 1500 microg/ml. The lung slices seem to be a more sensitive test system. SLN20 
      showed lower toxic values in all test systems. Therefore we conclude that SLN20 
      could be used as a suitable DDS for the lung, from a toxicological point of view.
FAU - Nassimi, Matthias
AU  - Nassimi M
AD  - Fraunhofer-Institut fur Toxikologie und Experimentelle Medizin ITEM, Hannover, 
      Germany.
FAU - Schleh, Carsten
AU  - Schleh C
FAU - Lauenstein, Hans-Dieter
AU  - Lauenstein HD
FAU - Hussein, Riem
AU  - Hussein R
FAU - Lubbers, Katrin
AU  - Lubbers K
FAU - Pohlmann, Gerhard
AU  - Pohlmann G
FAU - Switalla, Simone
AU  - Switalla S
FAU - Sewald, Katherina
AU  - Sewald K
FAU - Muller, Meike
AU  - Muller M
FAU - Krug, Norbert
AU  - Krug N
FAU - Muller-Goymann, Christel C
AU  - Muller-Goymann CC
FAU - Braun, Armin
AU  - Braun A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Inhal Toxicol
JT  - Inhalation toxicology
JID - 8910739
RN  - 0 (Drug Carriers)
RN  - 0 (Phospholipids)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - *Drug Carriers
MH  - Female
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Inhibitory Concentration 50
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Lung/*drug effects/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Microscopy, Confocal
MH  - Nanoparticles/*toxicity
MH  - Phospholipids/*toxicity
MH  - Risk Assessment
MH  - Tissue Culture Techniques
MH  - *Toxicity Tests
EDAT- 2009/06/30 09:00
MHDA- 2010/02/02 06:00
CRDT- 2009/06/30 09:00
PHST- 2009/06/30 09:00 [entrez]
PHST- 2009/06/30 09:00 [pubmed]
PHST- 2010/02/02 06:00 [medline]
AID - 10.1080/08958370903005769 [doi]
PST - ppublish
SO  - Inhal Toxicol. 2009 Jul;21 Suppl 1:104-9. doi: 10.1080/08958370903005769.